Yahoo Finance·2025-10-17 15:08Core Viewpoint - Novo Nordisk shares have significantly declined due to increased competition in the weight-loss drug market and recent comments from President Trump regarding price reductions for these medications [1][4]. Group 1: Market Impact - Shares of Novo Nordisk fell over 4% in early trading, while Eli Lilly's shares dropped by 3% following President Trump's announcement about potential price cuts for weight-loss drugs [2][3]. - President Trump indicated that the price of Novo Nordisk's Ozempic could decrease from $1,300 to $150 per month, which has raised concerns among investors [2][4]. Group 2: Competitive Landscape - Novo Nordisk has lost more than a third of its market value this year, attributed to intensifying competition in the weight-loss drug sector [1][4]. - Eli Lilly's shares have shown a slight increase of about 3% during the same period, indicating a different market response compared to Novo Nordisk [4]. Group 3: Regulatory Environment - The Centers for Medicare & Medicaid Services, led by Dr. Mehmet Oz, has not yet completed negotiations with pharmaceutical companies regarding drug pricing, which adds uncertainty to the market [2][5]. - A spokesperson from Novo Nordisk stated that the company is actively engaging with the Trump administration to find solutions for medication accessibility [4].